Caris Life Sciences Inc. is a patient-centric, next-generation artificial intelligence tech bio company and precision medicine provider. The Company develops and commercializes solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Its entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets. Its platform is purpose-built to leverage the convergence of next-generation sequencing (NGS), artificial intelligence (AI) and machine learning (ML) technologies, and high-performance computing. Its purpose-built, proprietary multi-omic profiling solutions capture and analyze molecular information from tissue and blood in a comprehensive manner. Its services for biopharma companies include prospective and retrospective profiling services, and companion diagnostics development.
äŒæ¥ã³ãŒãCAI
äŒç€ŸåCaris Life Sciences Inc
äžå Žæ¥Jun 18, 2025
æé«çµå¶è²¬ä»»è
ãCEOãHalbert (David Dean)
åŸæ¥å¡æ°- -
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«Jun 18
æ¬ç€Ÿæåšå°750 W. John Carpenter Freeway
éœåžIRVING
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœUnited States of America
éµäŸ¿çªå·75039
é»è©±çªå·18667718946
ãŠã§ããµã€ãhttps://www.carislifesciences.com/
äŒæ¥ã³ãŒãCAI
äžå Žæ¥Jun 18, 2025
æé«çµå¶è²¬ä»»è
ãCEOãHalbert (David Dean)
éå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã

ããŒã¿ãªã